MDRNA Releases In Vivo Cancer Data, Could Advance Bladder Cancer Program to Clinic First | GenomeWeb

By Doug Macron

MDRNA this week released in vivo data from its liver and bladder cancer programs, showing that the same RNAi construct, delivered via two different routes of administration, could reduce tumor size in mouse models of the diseases.

"I'm not sure anybody else has talked about the same compound having effect in two separate cancers via two separate routes of administration," MDRNA President and CEO Michael French told RNAi News. "We think that is … in the very least, encouraging."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.